Background: Additional to a child's genetic inheritance, environmental exposures are associated with schizophrenia. Many are broadly described as childhood adversity; modelling the combined impact of these is complex. We aimed to develop and validate a scale on childhood adversity, independent of genetic and other environmental liabilities, for use in schizophrenia risk analysis models, using data from cross-linked electronic health and social services registers.
Method: A cohort of = 428 970 Western Australian children born 1980-2001 was partitioned into three samples: scale development sample ( = 171 588), and two scale validation samples (each = 128 691). Measures of adversity were defined before a child's 10th birthday from five domains: discontinuity in parenting, family functioning, family structure, area-level socioeconomic/demographic environment and family-level sociodemographic status. Using Cox proportional hazards modelling of follow-up time from 10th birthday to schizophrenia diagnosis or censorship, weighted combinations of measures were firstly developed into scales for each domain, then combined into a final global scale. Discrimination and calibration performance were validated using Harrell's C and graphical assessment respectively.
Results: A weighted combination of 42 measures of childhood adversity was derived from the development sample. Independent application to identical measures in validation samples produced Harrell's Concordance statistics of 0.656 and 0.624. Average predicted time to diagnosis curves corresponded with 95% CI limits of observed Kaplan-Meier curves in five prognostic categories.
Conclusions: Our Early Adversity Scale for Schizophrenia (EAS-Sz), the first using routinely collected register data, predicts schizophrenia diagnosis above chance, and has potential to help untangle contributions of genetic and environmental liability to schizophrenia risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476059 | PMC |
http://dx.doi.org/10.1017/S0033291722001945 | DOI Listing |
BMC Psychiatry
January 2025
Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry, Takatsuki, 569-1041, Japan.
Background: Psychoeducation programs can reduce the risk of recurrence and readmission in patients with schizophrenia. However, almost all previous studies of program efficacy have included only patients completing the program, which may not be possible in all cases. The objective of this pilot cohort study was to compare the prognoses of inpatients with schizophrenia who did or did not complete a well-established institutional psychoeducation program.
View Article and Find Full Text PDFCommunity Ment Health J
January 2025
School of Public Health, The Unversity of Queensland, Brisbane, Queensland, Australia.
The Clubhouse Model of Psychosocial Rehabilitation provides non-clinical social support for adults living with a diagnosed mental illness or self-reported mental ill-health (referred to as 'members'). The Stepping Stone Clubhouse in Brisbane, Australia was evaluated between August 2022 and August 2023 using a participatory action research approach. Data was sourced from member surveys, member interviews, and an existing Clubhouse Member Database.
View Article and Find Full Text PDFSchizophrenia (Heidelb)
January 2025
Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020.
View Article and Find Full Text PDFClin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India.
Auditory/visual hallucinations and perceptual anomalies are one of the core symptoms experienced by patients with schizophrenia. Studies have implicated lateral occipital cortex (LOC) as one of the areas to be aberrantly functioning in schizophrenia, possibly associated with the auditory/visual symptoms of schizophrenia. Here we report of a case of a 29-year-old female diagnosed with treatment resistant schizophrenia on clozapine with persistent auditory verbal hallucinations (AVH) and visual anomalies.
View Article and Find Full Text PDFClin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
Rabbit syndrome (RS), characterized by fine, rapid, rhythmic movements along the mouth's vertical axis, is typically linked to prolonged antipsychotic medication use. Emerging evidence suggests newer antipsychotics' involvement in RS, prompting investigation into its association with long-acting injectable antipsychotics (LAIs) for schizophrenia or bipolar disorder. We report a case of RS observed in a patient diagnosed with bipolar I disorder and treated with Abilify Maintena, highlighting the importance of vigilance in monitoring adverse effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!